Teva Under Investigation For Creating ‘False Perceptions’ Of Generics
Case Puts Recent EU Antitrust Rulings Into the Spotlight
The European Commission is investigating whether Teva has “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.
You may also be interested in...
Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.
The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.
The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.